Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of VPM1002 to reduce COVID-19-related absenteeism in healthcare professionals
2020-001376-15Phase 3Terminated
- Sponsor
- Vakzine Projekt Management
- Start
- Apr 2020
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and Airways Infection comparing VPM1002 with Placebo (2 arms). Primary endpoint: Number of days absent from work due to respiratory disease. Started Apr 2020; status: terminated.
02
Drugs
VPM1002
03
Conditions
coronavirus disease 2019 (COVID-19)Airways Infection
Beyond the preview
Go deeper on 2020-001376-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001376-15.